rare: the income statement

MyFinsight

Ultragenyx Pharmaceutical Inc. (RARE)

For the quarter ending 2025-06-30, RARE made $166,496K in revenue. -$114,951K in net income. Net profit margin of -69.04%.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

	2025-06-30	2025-03-31	2024-09-30
Total revenues	166,496	139,292	139,494
Selling, general and administrative	86,646	87,797	80,351
Research and development	164,736	165,772	170,109
Cost of sales	23,002	28,662	21,021
Total operating expenses	274,384	282,231	271,481
Loss from operations	-107,888	-142,939	-131,987
Interest income	5,794	6,831	10,731
Change in fair value of equity investments	-9	-157	678
Non-cash interest expense on liabilities for sales of future royalties	14,041	14,342	15,712
Other income (expense)	2,140	837	3,077
Loss before income taxes	-114,004	-149,770	-133,213
Provision for income taxes	947	1,310	303
Net loss	-114,951	-151,080	-133,516

Earnings per share, basic, total	-1.17	-1.57	-1.4
Earnings per share, diluted, total	-1.17	-1.57	-1.4
Weighted average number of shares outstanding, basic, total	98,460,445	96,288,650	95,493,996
Weighted average number of shares outstanding, diluted, total	98,460,445	96,288,650	95,493,996

Unit: Thousand (K) dollars (except for numbers of shares and EPS)